Immix Biopharma, Inc. Balance Sheet
IMMX|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Immix Biopharma, Inc. had $23M in total assets and $16M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $17.7M | $17.7M | $17.5M |
| Current Assets | $20.2M | $20.2M | $19.8M |
| PP&E (Net) | $1.7M | $1.7M | $50.2K |
| Total Assets | $22.9M | $22.9M | $19.9M |
| Current Liabilities | $8.7M | $8.7M | $3.7M |
| Shareholders' Equity | $16.2M | $13.3M | $16.4M |